Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Chouin

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Cancers|September 25, 2020
Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in A Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual DiseaseSébastien Gouard, Catherine Maurel, Séverine Marionneau-Lambot, et al.
Ebiomedicine|June 21, 2024
Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female miceLoris Roncali, Séverine Marionneau-Lambot, Charlotte Roy, et al.
Frontiers in Oncology|March 3, 2020
SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for HumanFloriane Etienne, Maxime Berthaud, Frédérique Nguyen, et al.
Plos One|August 8, 2013
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212PbVincent Boudousq, Laure Bobyk, Muriel Busson, et al.
International Journal of Molecular Sciences|February 14, 2015
Tumor immunotargeting using innovative radionuclidesFrançoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, et al.
Oncotarget|March 7, 2018
Comparison of Immuno-PET of CD138 and PET imaging with <sup>64</sup>CuCl<sub>2</sub> and <sup>18</sup>F-FDG in a preclinical syngeneic model of multiple myelomaClément Bailly, Sébastien Gouard, Marie Lacombe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 13, 2024
Survival impact of [<sup>225</sup>Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastasesAlexandre Lugat, Nicolas Chouin, Florian Chocteau, et al.
International Journal of Molecular Sciences|May 30, 2019
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between <sup>89</sup>Zr- and <sup>64</sup>Cu-Labeled Anti-CD138 in a Preclinical Syngeneic ModelClément Bailly, Sébastien Gouard, François Guérard, et al.
Pharmaceutics|July 29, 2023
Preclinical Evaluation of a <sup>64</sup>Cu-Based Theranostic Approach in a Murine Model of Multiple MyelomaCassandra Métivier, Patricia Le Saëc, Joëlle Gaschet, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 2018
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian CancerEmmanuel Deshayes, Riad Ladjohounlou, Pierre Le Fur, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancers|September 25, 2020
Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in A Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual DiseaseSébastien Gouard, Catherine Maurel, Séverine Marionneau-Lambot, et al.
Ebiomedicine|June 21, 2024
Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female miceLoris Roncali, Séverine Marionneau-Lambot, Charlotte Roy, et al.
Frontiers in Oncology|March 3, 2020
SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for HumanFloriane Etienne, Maxime Berthaud, Frédérique Nguyen, et al.
Plos One|August 8, 2013
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212PbVincent Boudousq, Laure Bobyk, Muriel Busson, et al.
International Journal of Molecular Sciences|February 14, 2015
Tumor immunotargeting using innovative radionuclidesFrançoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, et al.
Oncotarget|March 7, 2018
Comparison of Immuno-PET of CD138 and PET imaging with <sup>64</sup>CuCl<sub>2</sub> and <sup>18</sup>F-FDG in a preclinical syngeneic model of multiple myelomaClément Bailly, Sébastien Gouard, Marie Lacombe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 13, 2024
Survival impact of [<sup>225</sup>Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastasesAlexandre Lugat, Nicolas Chouin, Florian Chocteau, et al.
International Journal of Molecular Sciences|May 30, 2019
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between <sup>89</sup>Zr- and <sup>64</sup>Cu-Labeled Anti-CD138 in a Preclinical Syngeneic ModelClément Bailly, Sébastien Gouard, François Guérard, et al.
Pharmaceutics|July 29, 2023
Preclinical Evaluation of a <sup>64</sup>Cu-Based Theranostic Approach in a Murine Model of Multiple MyelomaCassandra Métivier, Patricia Le Saëc, Joëlle Gaschet, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 2018
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian CancerEmmanuel Deshayes, Riad Ladjohounlou, Pierre Le Fur, et al.
Pageof 4